- Recro Pharma (REPH +1.4%) prices its public offering of 6.5M shares of common stock at $6. Underwriters over-allotment is an additional 975K shares. Closing date is December 16.
- Net proceeds will fund the NDA and preparations for commercial activities for IV meloxicam and the planned Phase 3b program as well as general corporate purposes.